Contact
searchSearch
HMP Global

Follicular Lymphoma Topic Center

News
Location Creates Travel Burden and Treatment Inequities for Patients With DLBCL and FL
04/17/2026
Rebecca Amrick
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in...
04/17/2026
First Report Managed Care
News

Epcoritamab Plus R2 Shows Promise for R/R FL Treatment 
04/15/2026
Rebecca Amrick
A study assessing the impact of epcoritamab and rituximab plus lenalidomide (R2) in treating relapsed/refractory follicular lymphoma (R/R FL) found favorable results for patients.
A study assessing the impact of epcoritamab and rituximab plus lenalidomide (R2) in treating relapsed/refractory follicular lymphoma (R/R FL) found favorable results for patients.
A study assessing the impact of...
04/15/2026
First Report Managed Care
News
What Real-World Data Reveal About R/R DLBCL Care
04/13/2026
Rebecca Amrick
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments...
04/13/2026
First Report Managed Care
News
Epcoritamab Plus R2 Maintains Quality of Life in R/R Follicular
04/10/2026
Hannah Musick
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and...
04/10/2026
First Report Managed Care
News
Bispecific Antibodies in Non-Hodgkin Lymphoma Show Manageable Safety Profile in Meta-Analysis
04/10/2026
Rebecca Amrick
Bispecific antibodies in non-Hodgkin lymphoma show manageable safety, with common but mostly low-grade infections and hematologic toxicities.
Bispecific antibodies in non-Hodgkin lymphoma show manageable safety, with common but mostly low-grade infections and hematologic toxicities.
Bispecific antibodies in...
04/10/2026
First Report Managed Care
News
Epcoritamab Expands Treatment Options in Relapsed or Refractory Follicular Lymphoma
04/08/2026
Hannah Musick
Epcoritamab is emerging as a promising, subcutaneous bispecific antibody option for relapsed or refractory follicular lymphoma, offering high response rates and a manageable safety profile in heavily pretreated patients.
Epcoritamab is emerging as a promising, subcutaneous bispecific antibody option for relapsed or refractory follicular lymphoma, offering high response rates and a manageable safety profile in heavily pretreated patients.
Epcoritamab is emerging as a...
04/08/2026
First Report Managed Care
News
Long-Term Follow-up Confirms Durable Responses With Epcoritamab in R/R LBCL
03/30/2026
Lisa Kuhns, PhD, MD
At 3 years, epcoritamab continues to deliver durable responses and manageable safety in heavily pretreated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), with sustained remissions seen in a substantial proportion of...
At 3 years, epcoritamab continues to deliver durable responses and manageable safety in heavily pretreated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), with sustained remissions seen in a substantial proportion of...
At 3 years, epcoritamab...
03/30/2026
First Report Managed Care
News
CD3/CD20 Bispecific T-cell Engagers Show High Response Rates in Follicular Lymphoma
03/26/2026
Lisa Kuhns, PhD, MD
Bispecific CD3/CD20 T-cell engagers deliver striking response rates with manageable safety in follicular lymphoma, positioning them as a potential game-changer in earlier lines of therapy.
Bispecific CD3/CD20 T-cell engagers deliver striking response rates with manageable safety in follicular lymphoma, positioning them as a potential game-changer in earlier lines of therapy.
Bispecific CD3/CD20 T-cell...
03/26/2026
First Report Managed Care
News
Patient Outcomes After Epcoritamab or Glofitamab Failure in R/R LBCL
03/25/2026
Grace Taylor, MS, MA
Disease progression after treatment with bispecific antibodies such as glofitamab in relapsed or refractory large B-cell lymphoma (R/R LBCL) is associated with rapid relapse and poor survival outcomes, highlighting a critical unmet need for...
Disease progression after treatment with bispecific antibodies such as glofitamab in relapsed or refractory large B-cell lymphoma (R/R LBCL) is associated with rapid relapse and poor survival outcomes, highlighting a critical unmet need for...
Disease progression after...
03/25/2026
First Report Managed Care
News
CAR T-Cell Therapy and Bispecific Antibodies Diverge in Relapsed or Refractory DLBCL
03/25/2026
Hannah Musick
In relapsed or refractory diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR) T-cell therapy shows greater durability and survival benefits, while bispecific antibodies offer lower toxicity and more accessible outpatient...
In relapsed or refractory diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR) T-cell therapy shows greater durability and survival benefits, while bispecific antibodies offer lower toxicity and more accessible outpatient...
In relapsed or refractory...
03/25/2026
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Videos

What's New?

News
Location Creates Travel Burden and Treatment Inequities for Patients With DLBCL and FL
04/17/2026
Rebecca Amrick
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in...
04/17/2026
First Report Managed Care
News

Epcoritamab Plus R2 Shows Promise for R/R FL Treatment 
04/15/2026
Rebecca Amrick
A study assessing the impact of epcoritamab and rituximab plus lenalidomide (R2) in treating relapsed/refractory follicular lymphoma (R/R FL) found favorable results for patients.
A study assessing the impact of epcoritamab and rituximab plus lenalidomide (R2) in treating relapsed/refractory follicular lymphoma (R/R FL) found favorable results for patients.
A study assessing the impact of...
04/15/2026
First Report Managed Care
News
What Real-World Data Reveal About R/R DLBCL Care
04/13/2026
Rebecca Amrick
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments...
04/13/2026
First Report Managed Care
News
Epcoritamab Plus R2 Maintains Quality of Life in R/R Follicular
04/10/2026
Hannah Musick
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and...
04/10/2026
First Report Managed Care
News
Bispecific Antibodies in Non-Hodgkin Lymphoma Show Manageable Safety Profile in Meta-Analysis
04/10/2026
Rebecca Amrick
Bispecific antibodies in non-Hodgkin lymphoma show manageable safety, with common but mostly low-grade infections and hematologic toxicities.
Bispecific antibodies in non-Hodgkin lymphoma show manageable safety, with common but mostly low-grade infections and hematologic toxicities.
Bispecific antibodies in...
04/10/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use